search
Back to results

High Dose Influenza Vaccine in Nursing Home - Pilot Study

Primary Purpose

Influenza

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
HD Fluzone Vaccine
SD Fluzone Vaccine
Sponsored by
Insight Therapeutics, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Influenza focused on measuring Randomized Controlled Trial, Influenza, Influenza vaccine, Flu Vaccine, Fluzone, HD Fluzone, Nursing Homes, Hospitalization, Mortality, Health Care worker vaccination, ADL decline, Pilot, Effectiveness

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Long-term care facilities in one of the 122 cities that serve as Center for Disease Control and Prevention (CDC) surveillance sites

Exclusion Criteria:

  • Facilities already systematically administering HD vaccine to their residents
  • Facilities for whom over half the residents are on Medicare (short-stay)
  • Facilities in which over half the residents are on Medicare Part A (SNF)
  • Facilities having fewer than 50 long-stay residents
  • Hospital-based facilities
  • Facilities with more than 20% of the population under age 65
  • Facilities with mandated (employment-dependent) seasonal influenza vaccination
  • Facilities not submitting MDS data

Sites / Locations

  • Brown Univeristy
  • Insight Therapeutics

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

HD Fluzone Vaccine

SD Fluzone Vaccine

Arm Description

NH facilities randomized to receive high dose trivalent influenza vaccine (HD Fluzone) for the residents.

NH facilities randomized to standard dose trivalent influenza vaccine (SD Fluzone) for the residents.

Outcomes

Primary Outcome Measures

Total All-cause Hospitalizations
The primary outcome will establish our methodology for measuring all-cause hospitalizations using the Minimum Data Set (MDS).

Secondary Outcome Measures

Change in Residents' Functional Status
The secondary outcome will establish our methodology for measuring change in functional status of nursing home residents using Activities of Daily Living (ADL) data in the Minimum Data Set (MDS). A change in functional status is defined as a decline in physical functioning by at least 4 points on the 28-point ADL scale.

Full Information

First Posted
October 15, 2012
Last Updated
April 25, 2018
Sponsor
Insight Therapeutics, LLC
Collaborators
Brown University
search

1. Study Identification

Unique Protocol Identification Number
NCT01720277
Brief Title
High Dose Influenza Vaccine in Nursing Home - Pilot Study
Official Title
High Dose Influenza Vaccination and Morbidity and Mortality in U.S. Nursing Homes - A Pilot Evaluation
Study Type
Interventional

2. Study Status

Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
September 2012 (undefined)
Primary Completion Date
May 2013 (Actual)
Study Completion Date
May 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Insight Therapeutics, LLC
Collaborators
Brown University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this pilot evaluation is to help determine the feasibility and power needed to prospectively evaluate relative effectiveness of high-dose influenza vaccine in preventing influenza mortality and hospitalization in a nursing home population in the U.S., compared to the standard-dose influenza vaccine.
Detailed Description
Influenza remains the most common preventable respiratory viral infection of older adults. Older adults incur more than 90% of the disease burden, and those residing in nursing homes are the most affected subset given their immune senescence, multi-morbidity, and close living quarters. Each year, the majority of influenza-related hospitalizations occur during the period with the greatest influenza activity. Influenza vaccination has been associated with reduced hospitalization, strokes, heart attacks and death in non-institutional older adult populations, but the benefit of influenza vaccine for the oldest population has been questioned. The new high-dose influenza vaccine is considerably more immunogenic in older adults, and has recently been approved for use in individuals aged 65 years and older. No clinical data yet confirm whether the improved immunogenicity translates into added clinical benefit, such as further reduction in hospitalization or death. Estimating the benefit of influenza vaccination among older adults in long-term care settings using randomized controlled trials requires extensive effort and is costly. Instead, a pragmatic RCT in a nursing home population has several advantages as a model for comparing therapeutic approaches. This clinical trial aims to test the feasibility of our protocol for a subsequent larger study. We aim to demonstrate that we can recruit and enroll facilities; randomly assign and coordinate vaccine delivery; collect data; conduct site audits for data validation; create outcomes using multiple data sources; and conduct analyses.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza
Keywords
Randomized Controlled Trial, Influenza, Influenza vaccine, Flu Vaccine, Fluzone, HD Fluzone, Nursing Homes, Hospitalization, Mortality, Health Care worker vaccination, ADL decline, Pilot, Effectiveness

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
2957 (Actual)

8. Arms, Groups, and Interventions

Arm Title
HD Fluzone Vaccine
Arm Type
Experimental
Arm Description
NH facilities randomized to receive high dose trivalent influenza vaccine (HD Fluzone) for the residents.
Arm Title
SD Fluzone Vaccine
Arm Type
Active Comparator
Arm Description
NH facilities randomized to standard dose trivalent influenza vaccine (SD Fluzone) for the residents.
Intervention Type
Biological
Intervention Name(s)
HD Fluzone Vaccine
Other Intervention Name(s)
Fluzone High Dose influenza vaccine
Intervention Description
Nursing home residents over 65 years are allocated to receive high dose trivalent vaccine. Residents under 65 years are provided standard dose trivalent vaccine (TIV).
Intervention Type
Biological
Intervention Name(s)
SD Fluzone Vaccine
Other Intervention Name(s)
Fluzone influenza vaccine
Intervention Description
Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
Primary Outcome Measure Information:
Title
Total All-cause Hospitalizations
Description
The primary outcome will establish our methodology for measuring all-cause hospitalizations using the Minimum Data Set (MDS).
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Change in Residents' Functional Status
Description
The secondary outcome will establish our methodology for measuring change in functional status of nursing home residents using Activities of Daily Living (ADL) data in the Minimum Data Set (MDS). A change in functional status is defined as a decline in physical functioning by at least 4 points on the 28-point ADL scale.
Time Frame
1 year
Other Pre-specified Outcome Measures:
Title
Recruit, Enroll, and Randomize Nursing Homes Per Calculated Sample Size
Description
This outcome evaluates our ability to recruit and enroll nursing facilities that meet our inclusion and exclusion criteria, and ensure nursing home residents receive either high-dose or standard-dose influenza vaccine
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Long-term care facilities in one of the 122 cities that serve as Center for Disease Control and Prevention (CDC) surveillance sites Exclusion Criteria: Facilities already systematically administering HD vaccine to their residents Facilities for whom over half the residents are on Medicare (short-stay) Facilities in which over half the residents are on Medicare Part A (SNF) Facilities having fewer than 50 long-stay residents Hospital-based facilities Facilities with more than 20% of the population under age 65 Facilities with mandated (employment-dependent) seasonal influenza vaccination Facilities not submitting MDS data
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stefan Gravenstein, MD, MPH
Organizational Affiliation
Case Western Reserve University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ed Davidson, PharmD, MPH
Organizational Affiliation
Insight Therapeutics, LLC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Vincent Mor, PhD
Organizational Affiliation
Brown University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Brown Univeristy
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02903
Country
United States
Facility Name
Insight Therapeutics
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23510
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
12517228
Citation
Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 Jan 8;289(2):179-86. doi: 10.1001/jama.289.2.179.
Results Reference
background
PubMed Identifier
15367555
Citation
Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA. 2004 Sep 15;292(11):1333-40. doi: 10.1001/jama.292.11.1333.
Results Reference
background
PubMed Identifier
17142257
Citation
Hayward AC, Harling R, Wetten S, Johnson AM, Munro S, Smedley J, Murad S, Watson JM. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. BMJ. 2006 Dec 16;333(7581):1241. doi: 10.1136/bmj.39010.581354.55. Epub 2006 Dec 1.
Results Reference
background
PubMed Identifier
11382801
Citation
Deguchi Y, Nishimura K. Efficacy of Influenza Vaccine in Elderly Persons in Welfare Nursing Homes: Reduction in Risks of Mortality and Morbidity During an Influenza A (H3N2) Epidemic. J Gerontol A Biol Sci Med Sci. 2001 Jun;56(6):M391-4. doi: 10.1093/gerona/56.6.m391.
Results Reference
background
PubMed Identifier
22724499
Citation
Gozalo PL, Pop-Vicas A, Feng Z, Gravenstein S, Mor V. Effect of influenza on functional decline. J Am Geriatr Soc. 2012 Jul;60(7):1260-7. doi: 10.1111/j.1532-5415.2012.04048.x. Epub 2012 Jun 21.
Results Reference
background
PubMed Identifier
9521230
Citation
Barker WH, Borisute H, Cox C. A study of the impact of influenza on the functional status of frail older people. Arch Intern Med. 1998 Mar 23;158(6):645-50. doi: 10.1001/archinte.158.6.645.
Results Reference
background
PubMed Identifier
16368725
Citation
Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol. 2006 Apr;35(2):337-44. doi: 10.1093/ije/dyi274. Epub 2005 Dec 20.
Results Reference
background
PubMed Identifier
16360785
Citation
Simonsen L, Viboud C, Taylor R. Influenza vaccination in elderly people. Lancet. 2005 Dec 17;366(9503):2086. doi: 10.1016/S0140-6736(05)67884-1. No abstract available.
Results Reference
background
PubMed Identifier
17625497
Citation
Fiore AE, Shay DK, Haber P, Iskander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NJ; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep. 2007 Jul 13;56(RR-6):1-54.
Results Reference
background
PubMed Identifier
11804444
Citation
Kingston BJ, Wright CV Jr. Influenza in the nursing home. Am Fam Physician. 2002 Jan 1;65(1):75-8, 72.
Results Reference
background
PubMed Identifier
12583681
Citation
Menec VH, Black C, MacWilliam L, Aoki FY. The impact of influenza-associated respiratory illnesses on hospitalizations, physician visits, emergency room visits, and mortality. Can J Public Health. 2003 Jan-Feb;94(1):59-63. doi: 10.1007/BF03405054.
Results Reference
background
PubMed Identifier
21496257
Citation
Mor V, Intrator O, Unruh MA, Cai S. Temporal and Geographic variation in the validity and internal consistency of the Nursing Home Resident Assessment Minimum Data Set 2.0. BMC Health Serv Res. 2011 Apr 15;11:78. doi: 10.1186/1472-6963-11-78.
Results Reference
background

Learn more about this trial

High Dose Influenza Vaccine in Nursing Home - Pilot Study

We'll reach out to this number within 24 hrs